On Tuesday, Apogee Therapeutics Inc (NASDAQ: APGE) opened lower -3.25% from the last session, before settling in for the closing price of $31.39. Price fluctuations for APGE have ranged from $29.64 to $72.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -47.74% at the time writing. With a float of $36.13 million, this company’s outstanding shares have now reached $45.99 million.
In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Apogee Therapeutics Inc (APGE) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Apogee Therapeutics Inc is 38.25%, while institutional ownership is 83.29%. The most recent insider transaction that took place on Feb 05 ’25, was worth 143,229. In this transaction Chief Medical Officer of this company sold 3,520 shares at a rate of $40.69, taking the stock ownership to the 252,623 shares. Before that another transaction happened on Feb 05 ’25, when Company’s Chief Executive Officer sold 15,000 for $40.58, making the entire transaction worth $608,700. This insider now owns 1,302,987 shares in total.
Apogee Therapeutics Inc (APGE) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -47.74% per share during the next fiscal year.
Apogee Therapeutics Inc (NASDAQ: APGE) Trading Performance Indicators
Check out the current performance indicators for Apogee Therapeutics Inc (APGE). In the past quarter, the stock posted a quick ratio of 18.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.23, a number that is poised to hit -1.21 in the next quarter and is forecasted to reach -5.84 in one year’s time.
Technical Analysis of Apogee Therapeutics Inc (APGE)
Compared to the last year’s volume of 0.56 million, its volume of 0.68 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 25.38%. Additionally, its Average True Range was 2.46.
During the past 100 days, Apogee Therapeutics Inc’s (APGE) raw stochastic average was set at 3.69%, which indicates a significant decrease from 15.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.65% in the past 14 days, which was lower than the 67.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $40.05, while its 200-day Moving Average is $46.40. Nevertheless, the first resistance level for the watch stands at $31.43 in the near term. At $32.48, the stock is likely to face the second major resistance level. The third major resistance level sits at $33.65. If the price goes on to break the first support level at $29.21, it is likely to go to the next support level at $28.04. Should the price break the second support level, the third support level stands at $26.99.
Apogee Therapeutics Inc (NASDAQ: APGE) Key Stats
There are currently 45,027K shares outstanding in the company with a market cap of 1.81 billion. Presently, the company’s annual sales total 0 K according to its annual income of -83,990 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -49,020 K.
